

# Pia S Zeiner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/778568/publications.pdf>

Version: 2024-02-01

18  
papers

793  
citations

933447

10  
h-index

888059

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1576  
citing authors

#	ARTICLE	IF	CITATIONS
1	The PI3K/Akt/mTOR pathway as a preventive target in melanoma brain metastasis. <i>Neuro-Oncology</i> , 2022, 24, 213-225.	1.2	36
2	Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy. <i>European Journal of Neurology</i> , 2022, 29, 543-554.	3.3	1
3	Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma. <i>Neurology</i> , 2022, 98, .	1.1	2
4	Linking epigenetic signature and metabolic phenotype in <i>IDH</i> mutant and <i>IDH</i> wildtype diffuse glioma. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 379-393.	3.2	4
5	A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 2373-2383.	2.5	2
6	DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma. , 2021, 9, e002226.		26
7	Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death. <i>Cancers</i> , 2020, 12, 2144.	3.7	6
8	Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas. <i>Acta Neuropathologica</i> , 2019, 138, 331-334.	7.7	22
9	Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. <i>Journal of Clinical Medicine</i> , 2019, 8, 2031.	2.4	23
10	Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas. <i>Brain Pathology</i> , 2019, 29, 513-529.	4.1	99
11	Area postrema syndrome as frequent feature of Bickerstaff brainstem encephalitis. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 1534-1542.	3.7	8
12	Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma. <i>Acta Neuropathologica Communications</i> , 2018, 6, 81.	5.2	22
13	Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. <i>Neuro-Oncology</i> , 2016, 18, 173-183.	1.2	35
14	ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, .	6.3	282
15	C5b-9 deposits on endomysial capillaries in non-dermatomyositis cases. <i>Neuromuscular Disorders</i> , 2016, 26, 283-291.	0.6	10
16	Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors. <i>PLoS ONE</i> , 2016, 11, e0155315.	2.5	18
17	<sc>MIF</sc> Receptor <sc>CD</sc>74 is Restricted to Microglia/Macrophages, Associated with a <sc>M</sc> Polarized Immune Milieu and Prolonged Patient Survival in Gliomas. <i>Brain Pathology</i> , 2015, 25, 491-504.	4.1	90
18	Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. <i>Oncotarget</i> , 2015, 6, 40836-40849.	1.8	106